Brannan Stephen K. 4

What Happened Stephen K. Brannan, a director of Serina Therapeutics (SER), reported an open-market/private purchase of 1,000 common shares on 2026-07-07 at $2.03 per share, for a total cash outlay of $2,030. This was a purchase (not a sale), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction date and price: 2026-07-07 — 1,000 shares @ $2.03 each.
• Total value: $2,030.
• Transaction type: Purchase (Form 4 code P — open market or private purchase as reported).
• Shares owned after transaction: Not specified in the filing.
• Filing date: 2026-07-09; the filing shows the report was submitted after the transaction date and does not indicate a late-filing notation.
• No 10b5-1 plan, tax withholding, option exercise, or other footnotes were reported for this transaction.

Context This is a straightforward insider purchase of common stock. The amount is relatively small ($2k), so while purchases can signal confidence, the dollar value here is modest. As always, insider buys are one data point; investors should combine this with company fundamentals and other disclosures.